Search results for ""
| Status | Drug name | NICE TAs | Comments | Subchapter |
|---|---|---|---|---|
 |
Metoclopramide suspension | Not recommended for patients aged 20 years and below due to risk of dystonic reactions. MHRA guidance - metroclopramide: risk of neurological adverse effects |
1.2 | |
|
Metoclopramide tablets | Not recommended for patients aged 20 years and below due to risk of dystonic reactions. MHRA guidance - metroclopramide: risk of neurological adverse effects |
1.2 | |
|
Metoclopramide tablets | 4.6 | ||
 |
Metolazone | Specialist recommendation (unlicensed). There is now a UK licensed metolazone 5mg tablet available (Xaqua®). There are significant differences in bioavailability between Xaqua® and alternative unlicensed imported metolazone preparations. Xaqua® tablets have up to approximately twice the bioavailability of other metolazone preparations. If switching from another metolazone product to Xaqua® tablets or vice versa, a dose adjustment may be necessary, and individualised titration based on patient's response and tolerability is advised. More information available from Specialist Pharmacy Service (SPS). We are awaiting guidance on switching to the licensed product – in the mean time please ensure that the patients are not inadvertently switched between products. |
2.2 | |
 |
Metoprolol injection | Hospital only |
2.4 | |
|
Metoprolol M/R tablets | 2.4 | ||
|
Metoprolol tablets | 2.4 | ||
|
Metranidazole gel 0.75% (Zidoval) | 7.2 | ||
|
Metronidazole (Anabact) 0.75% gel | Malodorous tumours and skin ulcers |
13.10 | |
|
Metronidazole 0.75% gel | Rozex for rosacea |
13.10 |
- First page
- Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- 193
- 194
- 195
- 196
- 197
- 198
- 199
- 200
- 201
- 202
- 203
- 204
- 205
- 206
- Next page
- Last page
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
